Ultrasound variables could help identify psoriasis patients at risk of progressing to PsAJanuary 26, 2022Psoriatic Arthritis
Generally mild/moderate nonserious adverse events in PsA patients treated with tofacitinibJanuary 26, 2022Psoriatic Arthritis
Ultrasound evaluation of entheses helps discriminate psoriatic arthritis from fibromyalgiaJanuary 26, 2022Psoriatic Arthritis
Real-world efficacy and safety of apremilast in patients with psoriatic arthritisJanuary 26, 2022Psoriatic Arthritis
Younger age at psoriasis diagnosis or severe disease tied to delayed transition from psoriasis to PsAJanuary 26, 2022Psoriatic Arthritis
Risankizumab shows promise in PsA patients with inadequate response to csDMARDsJanuary 26, 2022Psoriatic Arthritis
Psoriatic arthritis management should target both clinical and biochemical inflammationJanuary 26, 2022Psoriatic Arthritis
PsA: Upadacitinib shows similar benefits as monotherapy or in combination with nbDMARDsJanuary 26, 2022Psoriatic Arthritis
Discontinuing TNF inhibitors may not be required in PsA patients receiving BNT162b2 SARS-CoV-2 vaccineJanuary 26, 2022Psoriatic Arthritis
Proactive infliximab monitoring found best for sustaining control of inflammatory diseasesJanuary 10, 2022Psoriatic Arthritis
Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasisJanuary 4, 2022Psoriatic Arthritis
Spesolimab speeds lesion clearance in generalized pustular psoriasisDecember 27, 2021Psoriatic Arthritis
Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indicationDecember 15, 2021Psoriatic Arthritis
